Sector News

Celgene drops option to buy Abide, bags preclinical drug

March 28, 2018
Life sciences

Celgene has retooled its deal with Abide Therapeutics, dropping its takeout option and the drug that originally attracted it while picking up rights to another asset. The revisions see Abide regain control of a phase 2-ready CNS drug and pocket an upfront fee in exchange for an earlier-stage drug.

Summit, New Jersey-based Celgene paid $50 million for an option on the first two Abide assets to reach the clinic in 2014. And it handed over another $20 million to exercise its option on ABX-1431 two years later. The monoacylglycerol lipase (MGLL) inhibitor came through a phase 1b in Tourette syndrome late last year, at which point Abide hailed the safety and early signs of efficacy seen in the trial.

Months later, Celgene has walked away from the asset. Had Celgene stayed onboard, it would have been responsible for funding the phase 2 trial that Abide thinks the drug is now ready to enter.

Celgene’s actions loosen, but don’t sever, the ties between the two businesses. The big biotech no longer has a stake in ABX-1431 or an option to acquire Abide. But it has secured worldwide rights to a preclinical-stage asset in exchange for an upfront fee and milestone payments of undisclosed size.

Abide said little about the preclinical program, ABX-1772, in its statement disclosing the changes but it shared some details in a previous version of its publicly disclosed pipeline. The document listed ABX-1772 as targeting MGLL—the same target as ABX-1431—and fatty acid amide hydrolase (FAAH). FAAH is another member of the serine hydrolase enzyme family that is at the heart of Abide’s R&D.

Abide pegged the dual targeting of MGLL and FAAH as a way to treat epilepsy but has sold up before learning whether that thinking translates into human testing. Focal seizures and rare epilepsy syndromes were also on Abide’s R&D roadmap for the CNS-penetrating dual inhibitor. Celgene will now take the drug forward as holder to the worldwide rights.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

June 8, 2024

Lilly CFO leaves to join Alphabet

Life sciences

Anat Ashkenazi will leave Eli Lilly’s executive suite at the end of July to become CFO and senior vice president of Google and Alphabet. Ashkenazi has been CFO at Lilly since 2021 and originally joined the company in 2001. Over her 23-year career at the Indianapolis-based drugmaker, Ashkenazi also served as controller, CFO of Lilly Research Laboratories and as the finance chief for several global divisions within the company.

June 8, 2024

Edwards Lifesciences to cell Critical Care to BD

Life sciences

Edwards Lifesciences (NYSE: EW) announced it has entered into a definitive agreement to sell its Critical Care product group to BD (Becton, Dickinson and Company), in an all-cash transaction valued at $4.2 billion. With this agreement, Edwards is no longer pursuing the previously announced spin-off of Critical Care.

June 8, 2024

Danaher names Martin Stumpe as chief data and AI officer

Life sciences

The company, which owns diagnostics and life sciences businesses including Beckman Coulter and Cepheid, said the appointment reflects its increasing investment in AI as “a driving force for innovation and productivity.” Danaher is focused on AI by also spending on its internal capabilities and partnering with academic groups.

How can we help you?

We're easy to reach